Changes in levels of fractional exhaled and nasal nitric oxide after treatment in allergic rhinitis
10.4168/aard.2022.10.3.153
- Author:
Sanghwa HONG
1
;
Chae-Gu JO
;
Hyuna KIM
;
Young-Seok LEE
;
Woo Yong BAE
;
Jin-A JUNG
Author Information
1. Departments of Pediatrics, Dong-A University College of Medicine, Busan, Korea Purpose: Recent studies have reported that nasal nitric oxide (NO) increases in patients with allergic rhinitis
- Publication Type:ORIGINAL ARTICLE
- From:Allergy, Asthma & Respiratory Disease
2022;10(3):153-157
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Recent studies have reported that nasal nitric oxide (NO) increases in patients with allergic rhinitis (AR) and bronchial asthma (BA), and can be used as a noninvasive test to determine treatment efficacy. We aimed to investigate the changes in fractional exhaled NO (FeNO) and nasal NO levels before and after treatment in patients with AR and asthma.
Methods:Children aged 6–18 years who visited Dong-A University Hospital from August 2013 to July 2014 were treated for mildpersistent or severe-intermittent AR according to Allergic Rhinitis and its Impact on Asthma guidelines. FeNO and nasal NO were measured using NObreath. Among all patients, rhinitis was treated for 1 month, and the results were evaluated in patients with improved AR (n = 31), improved AR+BA (n = 23), and control (n = 19) groups.
Results:Sex, age, body mass index, allergy, serum total eosinophil count and immunoglobulin E, erythrocyte sedimentation rate, and C-reactive protein showed no intergroup differences before or after treatment. Nasal NO before treatment was higher in the BA+AR and AR groups than controls (P = 0.005), but there was no difference between disease groups after treatment. Both groups showed a significant decrease in nasal NO after treatment compared with measurements before treatment (AR, P = 0.044; AR+BA, P = 0.004).
Conclusion:Nasal NO can be effectively used as a noninvasive test for clinical efficacy because it was significantly reduced by improving symptoms in AR patients with and without asthma.
